Abstract

Sepsis is the leading cause of death in critically ill patients. While decreased Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) function improves clinical outcomes in murine and human sepsis, the mechanisms involved have not been fully elucidated. We tested the hypothesis that lipopolysaccharide (LPS), the major Gram-negative bacteria endotoxin, is cleared from the circulation by hepatocyte Low Density Lipoprotein Receptors (LDLR)—receptors downregulated by PCSK9. We directly visualized LPS uptake and found that LPS is rapidly taken up by hepatocytes into the cell periphery. Over the course of 4 hours LPS is transported towards the cell center. We next found that clearance of injected LPS from the blood was reduced substantially in Ldlr knockout (Ldlr-/-) mice compared to wild type controls and, simultaneously, hepatic uptake of LPS was also reduced in Ldlr-/- mice. Specifically examining the role of hepatocytes, we further found that primary hepatocytes isolated from Ldlr-/- mice had greatly decreased LPS uptake. In the HepG2 immortalized human hepatocyte cell line, LDLR silencing similarly resulted in decreased LPS uptake. PCSK9 treatment reduces LDLR density on hepatocytes and, therefore, was another independent strategy to test our hypothesis. Incubation with PCSK9 reduced LPS uptake by hepatocytes. Taken together, these findings demonstrate that hepatocytes clear LPS from the circulation via the LDLR and PCSK9 regulates LPS clearance from the circulation during sepsis by downregulation of hepatic LDLR.

Highlights

  • Septic shock is a complication of a severe microbial infection that triggers an uncontrolled systemic inflammatory response and subsequent organ failure

  • In Ldlr-/- mice LPS clearance from plasma was decreased compared to wild type mice after 1 (p = 0.0021) and 6 hours (p = 0.0249) (Fig 2A) suggesting that in vivo clearance of LPS from plasma is Low Density Lipoprotein Receptors (LDLR)-dependent

  • Data presented as mean±SEM, (***P = 0.0007, compared with control 1h; **P = 0.0026, compared with control 6h, n = 3). (C) Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) further altered uptake of LPS in HepG2 cells with LDLR knockdown

Read more

Summary

Introduction

Septic shock is a complication of a severe microbial infection (sepsis) that triggers an uncontrolled systemic inflammatory response and subsequent organ failure. Effective treatment of severe sepsis can lead to complete resolution while ineffective treatment can be fatal [1]. Beyond antibiotic therapy there are currently no effective treatments for septic shock. KRW, JHB, and JAR have founded Cyon Therapeutics, which has licensed this intellectual property. KRW, JHB, and JAR are share holders and board members of Cyon Therapeutics. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials as there was no restriction on sharing this data

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.